Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
about
Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.Chronic viral hepatitis C: management updateAttacking pathogens through their hostsClinical guidelines on the management of hepatitis CAnti-hepatitis C virus drugs and kidneyVirus movements on the plasma membrane support infection and transmission between cellsThe hepatic flaviviridae: summary.Hepatitis C: retreatment and treatment of patients with renal failure.Adverse effects and other safety aspects of the hepatitis C antivirals.IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.Evolution of interferon-based therapy for chronic hepatitis C.Hepatitis C advances in antiviral therapy: what is accepted treatment now?Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patientsPeginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection.Evaluating the evidence from clinical trials in chronic hepatitis C.Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapyAntiviral treatment of hepatitis C.Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureOphthalmologic complications of antiviral therapy in hepatitis C treatment.Is the 25-year hepatitis C marathon coming to an end to declare victory?African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study.Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.Efficacy of interferon therapy in elderly patients with chronic hepatitis C.Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study.Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus.Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon.Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.European guideline for the management of hepatitis B and C virus infections.
P2860
Q24805127-01742FC0-09BE-47C0-A71C-EF957A991E9CQ27469364-BCB40D9B-61F0-4FC2-967D-F7231914080BQ27471844-98752A2F-EB24-4DBC-B748-2010A19B5A94Q27473132-715D59E6-B2E3-4CAD-97AD-FB88B6C5B6A6Q27477946-566E0D51-053F-43FC-9CF8-BAA92FE54B34Q28070279-68C64EF8-3E3A-4029-863C-4F9AEB528DD5Q30944807-7F72F5D8-E923-4DFE-97D3-DD5FBE2B9A06Q33888790-8339D0E3-5B14-4200-BF28-7A2222FD7B90Q33988112-F5BCE673-F587-4555-8E77-F8C11F03CEB2Q33988126-79447F92-F4A4-427A-A527-EC2510036008Q34164822-AAEB8719-64D2-4754-AC90-430C76526FD8Q34342092-ECAA7CD7-C60A-4555-B275-56BEDF3C3374Q34619384-1E342837-EEA2-466E-B718-F809ABE0A8BCQ34799396-5F0E00FF-1A2E-4C83-B68E-2EACD74C19E4Q35473208-7A947B3E-BA29-4639-A4AB-72D3881497B2Q35621342-A046157B-51D3-4E96-9F2D-2E6DCFE98DF1Q35917238-F99891DA-FD0E-4C2E-B814-9D9B975D2194Q36455990-B80C9AA1-9A59-4F3F-9574-B2107BBA3627Q36491967-E821BA29-7B2A-4A45-A53C-4AEFBFA5622AQ36613917-7996A55B-28FD-4AAD-9103-1D80A4241855Q37050953-55E72615-D0A6-47CC-B327-3CF7C6B102F1Q37135584-16487344-38B4-4060-A650-F44494CD4408Q37378913-1746BD32-EC09-4C08-96BE-898B11A7D94AQ38556915-7B27659A-967A-4302-800E-8EF5E7D748D5Q39573613-54A37CBC-F108-47D4-B6AF-09C990874DCBQ40547796-0F8334C1-4D2C-4C9B-9156-FCA1A71B530AQ42989123-FCCACA6F-5843-403F-AEEA-7EF0338A8EFDQ42992922-69144BAE-573A-43CB-A348-CBE8FC305057Q42992965-D4B7E539-9C0B-41A8-BA91-97B62FFD50BFQ42995573-A0421CF2-F0A5-4B72-8957-B2838EEA417BQ42996562-9E5D1332-F2F8-4FC9-89F9-22550A4F9313Q42997762-499F5C74-02A2-40F3-B4C9-AF09693A1DD7Q42999262-6C99925F-13B8-4EAD-BB81-FC651B6427A0Q43000772-C9B2487B-D0C1-46AF-BBF4-69CC64491184Q43001306-E47964BE-FBA8-4DB5-A1CB-596FE1E755EAQ43031055-8017DC9E-37D0-40EE-8839-C5CDD44FA6AAQ43039948-AF3BC3D9-303D-44BA-827F-EA5AC57CAACBQ43514787-721B6705-2FDF-4E48-954A-C3FB65B18885Q43892504-549EB047-C004-4802-B123-7A690F486699Q44118049-CD6025B2-5BC9-4F74-B7F0-612F5AA638CB
P2860
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Ribavirin enhances the efficac ...... nt data from European centers.
@en
type
label
Ribavirin enhances the efficac ...... nt data from European centers.
@en
prefLabel
Ribavirin enhances the efficac ...... nt data from European centers.
@en
P2093
P1476
Ribavirin enhances the efficac ...... ent data from European centers
@en
P2093
A Bellobuono
J T Brouwer
L Cavalletto
L Chemello
R Schvarcz
S W Schalm
P304
P356
10.1016/S0168-8278(97)80103-1
P577
1997-05-01T00:00:00Z